When Aβ begins to accumulate, GSK-3β is activated and the classical β-catenin pathway is downregulated in the pathogenesis of AD by decreasing the level of β-catenin or increasing the activity of GSK-3β and Dickkopf-1 [43,44,45]. This evidence concerns the gene GSK3B and Alzheimer disease.